A Phase 1/2 interventional study of DCC-3009 and Rabeprazole in Gastrointestinal Stromal Tumor (GIST), sponsored by Deciphera Pharmaceuticals, LLC. Recruiting at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Deciphera Pharmaceuticals, LLC (part of Ono Pharmaceutical Co. Ltd) · Phase 1/2, Interventional, and Treatment
How we know · 6 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Gastrointestinal Stromal Tumors by Ono Pharmaceutical Co. Ltd — 2 open to participants now, 5 under way, 2 of them phase 3. Gastrointestinal Stromal Tumors · Ono Pharmaceutical Co. Ltd.
Among the 10 studies in Gastrointestinal Stromal Tumors by Ono Pharmaceutical Co. Ltd, this one is the only one that started in 2024, is one of 3 in phase 1/2, and was the 9th registered.
343 studies on the registry are indexed under Gastrointestinal Stromal Tumors; 61 are open to participants now.
Browse Gastrointestinal Stromal Tumors studies →2 of the 10 studies in Gastrointestinal Stromal Tumors by Ono Pharmaceutical Co. Ltd are open now, in 2 countries. Recruiting first, the newest first:
Ono Pharmaceutical Co., Ltd. · Sites in Japan
Ages 18+
By country, each count listing its studies:
Of the 49 Gastrointestinal Stromal Tumors studies recruiting now, 38 (78%) set no upper age limit and 4 (8%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 3 · Phase 3 3
First in 2015; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 155 is above the median of 50 across 252 interventional studies indexed under Gastrointestinal Stromal Tumors.
Median enrollment 94 across the 9 interventional studies. Of the 3 that completed or were terminated, 1 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Deciphera Pharmaceuticals, LLC, one of the names counted as Ono Pharmaceutical Co. Ltd. Under that name alone:
Deciphera Pharmaceuticals, LLC is the lead sponsor of 24 studies on the registry; 5 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 3 (30%) have results posted.
1 of the studies in Gastrointestinal Stromal Tumors by Ono Pharmaceutical Co. Ltd that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05957367Deciphera Pharmaceuticals, LLCA Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Gastrointestinal Stromal Tumors by Ono Pharmaceutical Co. Ltd, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this Phase 1/2 master protocol study is to evaluate if DCC-3009 is safe, tolerable and works effectively in the treatment of GIST. The study will use a modular approach with each module being defined according to therapy: DCC-3009 alone or DCC-3009 in combination with other anticancer therapies. Each module will be conducted in 3 parts: Part 1 (Dose Escalation), Part 2 (Dose Expansion), and Part 3 (Food Effect [FE] and Drug-Drug Interaction [DDI]). Participants will be treated in 28-day treatment cycles with an estimated duration of up to 2 years.
The criteria were revised on the registry on Nov 12, 2026. See what changed
Key Inclusion Criteria:
Module A:
Module A Part 1 (Escalation) and Part 3 (FE and DDI):
-Any participant with or cytologically confirmed advanced/unresectable or GIST with documented KIT or -derived growth factor receptor alpha (PDGFRA) mutation, who has progressed on or was intolerant to at least 1 approved tyrosine kinase inhibitor (TKI) regimen in the advanced/metastatic setting
Module A Part 2 (Expansion):
-Any participant with histologically or cytologically confirmed advanced or metastatic GIST with documented KIT or PDGFRA mutation
Module A Part 3 (FE and DDI):
-Able to consume a high-fat meal
Key Exclusion Criteria:
Module A Part 3 (FE and DDI):
Other protocol-specified inclusion and exclusion criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
iRECIST and mRECIST
Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive DCC-3009 in 28 day cycles in Module A Part 1 dose escalation, Part 2 dose expansion, and Part 3 FE and DDI. Participants in Part 3 will also receive rabeprazole.
Drug: DCC-3009 · Drug: Rabeprazole
Administered orally
Administered orally (Part 3 only)
Number of Participants with Dose-Limiting Toxicities (DLT) (Part 1 Escalation)
DLTs assessed for each dose level.
Time frame: Cycle 1 (28 Days)
Number of Participants with Treatment-emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs) (Part 1 Escalation)
Time frame: Cycle 1 (28 Days)
Number of Participants with Dose Reduction, Interruption, or Discontinuation of Study Drug Due to TEAEs (Part 1 Escalation)
Time frame: Cycle 1 (28 Days)
Objective Response Rate (ORR) (Part 2 Expansion)
ORR is the percentage of participants with confirmed complete response (CR) or confirmed partial response (PR) based on Modified Response Evaluation Criteria in Solid Tumors (mRECIST), v1.1.
Time frame: Baseline to Progressive Disease (PD), Death due to Any Cause, or Start of New Antitumor Therapy (Estimated up to 24 months)
Pharmacokinetics (PK): Time to Maximum Observed Plasma Concentration (Tmax) (Part 3 FE and DDI)
Time frame: Estimated up to 24 months
PK: Maximum Observed Plasma Drug Concentration (Cmax) (Part 3 FE and DDI)
Time frame: Estimated up to 24 months
PK: Trough Plasma Concentration (Ctrough) (Part 3 FE and DDI)
Time frame: Estimated up to 24 months
PK: Area Under the Plasma Concentration-time Curve (AUC) (Part 3 FE and DDI)
Time frame: Estimated up to 24 months
Objective Response Rate (ORR) (Part 1 Escalation and Part 3 FE and DDI)
ORR is the percentage of participants with confirmed complete response (CR) or confirmed partial response (PR) based on mRECIST, v1.1.
Time frame: Baseline to Progressive Disease (PD), Death due to Any Cause, or Start of New Antitumor Therapy (Estimated up to 24 months)
Disease Control Rate (DCR)
DCR is the proportion of participants who achieve CR, PR, or stable disease at the specified time point per mRECIST, v1.1.
Time frame: Weeks 16, 24, 32
Duration of Response (DOR)
DOR for participants with confirmed CR or confirmed PR based on mRECIST, v1.1, defined as the time interval from the time that the measurement criteria are first met for CR or PR (whichever is first recorded) until the first date that the disease progression is objectively documented or death, whichever occurs first.
Time frame: First Recorded CR or PR until PD or Death (Estimated up to 24 months)
Time to Response (TTR)
TTR for participants with confirmed CR or confirmed PR based on mRECIST, v1.1, defined as the time from initiation of treatment until the first assessment demonstrating CR or PR per mRECIST, v1.1.
Time frame: Baseline to First Recorded CR or PR (Estimated up to 24 months)
Progression-Free Survival (PFS)
PFS is the time from initiation of treatment until documented disease progression per mRECIST, v1.1, or death, whichever occurs first.
Time frame: Initiation of Treatment to PD or Death (Estimated up to 24 months)
Overall Survival (OS)
OS is the time from initiation of treatment to the date of death from any cause.
Time frame: Initiation of Treatment to Death from Any Cause (Estimated up to 24 months)
PK: Tmax (Part 1 Escalation and Part 2 Expansion)
Time frame: Estimated up to 24 months
PK: Cmax (Part 1 Escalation and Part 2 Expansion)
Time frame: Estimated up to 24 months
PK: Ctrough (Part 1 Escalation and Part 2 Expansion)
Time frame: Estimated up to 24 months
PK: AUC (Part 1 Escalation and Part 2 Expansion)
Time frame: Estimated up to 24 months
Number of Participants with TEAEs or SAEs (Part 2 Expansion and Part 3 FE and DDI)
Time frame: Estimated up to 24 months
Number of Participants with Dose Reduction, Interruption, or Discontinuation of Study Drug Due to TEAEs (Part 2 Expansion and Part 3 FE and DDI)
Time frame: Estimated up to 24 months
Started Dec 2024 (actual). Primary completion is estimated for May 2028, 41 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Gastrointestinal Stromal Tumors →
Deciphera Pharmaceuticals, LLC →